Acasti Pharma to delist shares on TSXV, confirms no exposure to SVB

Acasti Pharma (ACST) announced that it has applied and received approval for a voluntary delisting of its common shares from the TSX Venture Exchange, TSXV. The delisting from the TSXV will not affect the Company’s listing on the NASDAQ Capital Market. The common shares will continue to trade on the NASDAQ under the symbol "ACST". The Company believes that the trading volume of its shares on the TSXV no longer justifies the expenses and administrative efforts required to maintain a dual listing. The Company also believes that delisting from the TSXV will create a central marketplace for its common shares on the NASDAQ, and ultimately benefit the long-term liquidity and shareholder value of the Company. It is anticipated that, effective as at the close of trading on March 27, 2023, Acasti’s common shares will no longer be listed and posted for trading on the TSXV. The Company also confirms that neither Acasti, nor any of its subsidiaries have any exposure to Silicon Valley Bank, SVB, (SIVB) or Silvergate Bank. The Company has no deposits with those institutions, and has been financed through equity issuances in the past and not from any form of debt or other interest bearing securities